Dopamine concentrations in the rat brain following injections into the substantia nigra of baclofen, gamma-aminobutyric acid, gamma-hydroxybutyric acid, apomorphine and amphetamine

Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum

gamma-Hydroxybutyrate (GHB) is an endogenous metabolite of gamma-aminobutyric acid (GABA), which is synthesized in the neuronal compartment of the central nervous system. This substance possesses several properties that support its role as a neurotransmitter/neuromodulator in brain. In particular, it is synthesized by a specific pathway that transforms GABA into succinic semialdehyde via GABA-T activity; then succinic semialdehyde is converted into GHB by a specific succinic semialdehyde reductase (SSR). The last enzyme is considered as a marker for neurons that synthesize GHB. This compound binds in brain to receptors whose distribution, ontogenesis, kinetics, and pharmacology are specific. Endogenous GHB, but also GHB exogenously administered to rats, participate in the regulation of dopaminergic activity of the nigrostriatal pathway. To investigate the distribution of GHB neurons in this pathway and the anatomic relationships between dopaminergic and GHB neurons, immunocytochemical identification of dopamine, GABA, and GHB neurons was carried out in the substantia nigra and striatum of the rat. The following markers for these neurons were used: anti-tyrosine hydroxylase (TH) antibodies for dopamine neurons, anti-glutamate decarboxylase (GAD) antibodies for GABA neurons, and anti-succinic semialdehyde reductase (SSR) antibodies for GHB neurons. GABA neurons were studied because GAD and SSR co-exist frequently in the same neuron, and GABA alone also exerts its own regulatory effects on dopaminergic neurons. This study reveals the co-existence of GAD/SSR and GAD/SSR/TH in numerous neurons of the substantia nigra. However, some neurons appear to be only GAD or SSR positive. In the striatum, TH-positive terminals surround many GHB neurons. GAD innervation is abundant in close contact with unlabeled neurons in the caudate-putamen, whereas distinct SSR-positive punctuates are also present. The existence of SSR-reactive synapses and neurons was confirmed in the striatum at the electron microscopic level. On the basis of these results, a clear anatomo-functional relationship between GHB and dopamine networks cannot be defined; however, we propose the modulation by GHB of striatal intrinsic neurons that could then interfere with the presynaptic control of dopaminergic activity.

Alcoholism abolishes the gamma-aminobutyric acid (GABA)ergic control of GH secretion in humans

In order to establish possible alterations in the gamma-aminobutyric acid (GABA)ergic control of growth hormone (GH) secretion in alcoholics, 800 mg sodium valproate (a drug enhancing endogenous GABA activity), 10 mg baclofen (a GABA(B) receptor agonist) or a placebo were given orally to nine normal men (age 38-48 years) and nine 2-4-week-abstinent alcoholics (age 35-50 years; duration of alcohol consumption 3-6 years). Blood samples for GH assay were taken every 30 min for the next 150 min. Both drugs induced a significant increment in serum GH levels in the normal controls; mean peak was 7.2 and 3.27 times higher than baseline after sodium valproate and baclofen, respectively. In contrast, GH secretion in alcoholic patients did not change after baclofen or sodium valproate administration. Placebo administration did not modify GH secretion in any subject. In concurrence with previous reports showing alterations of GABAergic neurotransmission in the central nervous system of patients affected by alcoholism, these data show the loss of the GABAergic mechanism(s) underlying the GH response to sodium valproate and/or baclofen action in alcoholism.

Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells

Five days of gamma-hydroxybutyrate (GHB) administration (3 x 500 mg kg(-1) day(-1) i.p.) to rats resulted in a significant decrease in the density of GHB receptors measured in the whole rat brain without modification of their corresponding affinity. Similar administration of (-)-sulpiride (2 X 100 mg kg(-1) day(-1) i.p. for 5 days) induces an up-regulation of GHB receptors without change in their dissociation constants (Kd). Haloperidol (2 X 2 mg day(-1) i.p. for 5 days) showed no effect. Administered chronically via osmotic minipumps directly into the lateral ventricles, (-)-sulpiride (60 microg day(-1) for 7 days) and GHB (600 microg day(-1) for 7 days) up-regulated and down-regulated rat brain GHB receptors, respectively. Finally, in a mouse hybridoma cell line (NCB-20 cells) expressing GHB receptors, the treatment of these cells with 1 mM GHB, 100 microM (-)-sulpiride or 1 mM GABA decreases, increases and induces no change, respectively, in the density of GHB receptors after 3 days of treatments. These results indicate that chronic GHB treatment modifies the expression of its receptor and that sulpiride also induces plastic changes in GHB receptors perhaps via antagonistic properties.

The gamma-hydroxybutyrate signalling system in brain: organization and functional implications

gamma-Hydroxybutyrate is a metabolite of GABA which is synthesized and accumulated by neurons in brain. This substance is present in micromolar quantities in all brain regions investigated as well as in several peripheral organs. Neuronal depolarization releases gamma-hydroxybutyrate into the extracellular space in a Ca(2+)-dependent manner. Gamma-hydroxybutyrate high-affinity receptors are present only in neurons, with a restricted specific distribution in the hippocampus, cortex and dopaminergic structures of rat brain (the striatum in general, olfactory bulbs and tubercles, frontal cortex, dopaminergic nuclei A9, A10 and A12). Stimulation of these receptors with low amounts of gamma-hydroxybutyrate induces in general hyperpolarizations in dopaminergic structures with a reduction of dopamine release. However, in the hippocampus and the frontal cortex, it seems that gamma-hydroxybutyrate induces depolarization with an accumulation of cGMP and an increase in inositol phosphate turnover. Some of the electrophysiological effects of GHB are blocked by NCS-382, a gamma-hydroxybutyrate receptor antagonist while some others are strongly attenuated by GABAB receptors antagonists. Gamma-hydroxybutyrate penetrates freely into the brain when administered intravenously or intraperitoneally. This is a unique situation for a molecule with signalling properties in the brain. Thus, the gamma-hydroxybutyrate concentration in brain easily can be increased more than 100 times. Under these conditions, gamma-hydroxybutyrate receptors are saturated and probably desensitized and down-regulated. It is unlikely that GABAB receptors could be stimulated directly by GHB. Most probably, GABA is released in part under the control of GHB receptors in specific pathways expressing GABAB receptors. Alternatively, GABAB receptors might be specifically stimulated by the GABA formed via the metabolism of gamma-hydroxybutyrate in brain. In animals and man, these GHBergic and GABAergic potentiations induce dopaminergic hyperactivity (which follows the first phase of dopaminergic terminal hyperpolarization), a strong sedation with anaesthesia and some EEG changes with epileptic spikes. It is presumed that, under pathological conditions (hepatic failure, alcoholic intoxication, succinic semialdehyde dehydrogenase defects), the rate of GHB synthesis or degradation in the peripheral organ is modified and induces increased GHB levels which could interfere with the normal brain mechanisms. This pathological status could benefit from treatments with gamma-hydroxybutyric and/or GABAB receptors antagonists. Nevertheless, the regulating properties of the endogenous gamma-hydroxybutyrate system on the dopaminergic pathways are a cause for the recent interest in synthetic ligands acting specifically at gamma-hydroxybutyrate receptors and devoid of any role as metabolic precursor of GABA in brain.

The spontaneous release of acetylcholinesterase in rat substantia nigra is altered by local changes in extracellular levels of dopamine

Acetylcholinesterase release in the guinea-pig substantia nigra has been previously investigated 'on-line', using a sensitive chemiluminescent system. Since histological observations suggest that there is a difference in acetylcholinesterase distribution in the rat substantia nigra compared to that of the guinea-pig, the first aim of the present study was to use this chemiluminescent method to characterise acetylcholinesterase release in this brain region of the freely moving rat, and the second was explore the relationship between acetylcholinesterase release and dopamine systems in this region. Accordingly, acetylcholinesterase release in the rat substantia nigra was studied under basal conditions of spontaneous release and following the local administration of (a) elevated potassium ions (30, 45, 60'mM), (b) a stimulator of dopamine/acetylcholinesterase release-D-amphetamine (10(-7), 10(-6) and 10(-5) M), (c) an inhibitor of dopamine uptake-GBR12909 (10(-7), 10(-6) and 10(-5) M). Spontaneous release of acetylcholinesterase in this brain region of the rat appears to be comparable with that observed in the guinea-pig, despite the smaller number of acetylcholinesterase-containing neurones. Furthermore, not only elevated potassium ions, but D-amphetamine as well as GBR12909, all produced significant increases in the percentage spontaneous release of acetylcholinesterase. Thus, the release of acetylcholinesterase in this region may be triggered by levels of dopamine outside of the neurone.

Gamma hydroxybutyrate is not a GABA agonist

Gamma hydroxybutyrate (GHB) is primarily known and used as a relatively specific inhibitor of central DA release. However, it is also widely assumed to be an agonist or prodrug of gamma-aminobutyric acid (GABA) and its central activity has been attributed to an action exerted at GABA receptors. Nevertheless, there is compelling evidence that: (1) GHB formation may occur independently of GABA; (2) GHB is behaviorally, biochemically and physiologically distinct from GABA in many ways, and does not consistently effect GABAA or GABAB agonist induced responses; (3) GHB has little effect on either GABAA or GABAB receptors at less than millimolar concentrations. Consequently, GHB does not appear to be either a GABA prodrug or a GABA agonist. However, the GHB metabolite gamma butyrolactone (GBL) may possess some limited GABA agonist activity.

Failure of the gamma-aminobutyric acid (GABA) derivative, baclofen, to stimulate growth hormone secretion in heroin addicts

In order to establish possible alterations in the gamma aminobutyric acid (GABA)ergic control of growth hormone (GH) secretion in heroin addicts, ten patients (age, 25.8 +/- 1.07 yr (mean +/- SE); duration of heroin addiction, range 3-8 yr; weight, 67.3 +/- 0.87 kg body weight), and ten age (29.1 +/- 0.84 yr)- and weight (69.7 +/- 0.87 kg)-matched normal controls were tested with the GABAergic B-receptor agonist baclofen (10 mg p.o. at 09.00 h) (experimental test) or a placebo (control test). Blood samples for GH assay were taken every 15 min for the next 150 min. Normal controls underwent one control and one experimental test. Heroin addicts were submitted to both baclofen and placebo test twice, once around the time of their admission to a recovery community for drug abusers, when they were still assuming heroin, and again after two months of permanence in the community. From the time of their admission to the community, the patients were forbidden to use heroin. For two weeks after admission they were treated with clonidine and acetylsalicilic acid to attenuate withdrawal symptoms. Thereafter, the patients underwent a period of wash-out of pharmacological treatments for at least 6 weeks before being retested. Basal GH levels were similar in normal controls and heroin addicts in all tests and remained unmodified during control tests in all subjects. The administration of baclofen increased four times the serum GH levels within 120 minutes in the normal controls, whereas it did not modify serum GH concentrations in heroin addicts either during the period of drug abuse or after two months of abstinence. These data show that the control of GH secretion mediated by GABAergic B-receptors is impaired in heroin addicts. It is hypothesized that this neuroendocrine alteration might represent a trait marker of heroin addiction, or more likely, that it was a consequence of a long addiction to heroin persisting after two months of abstinence.

Facilitation of amphetamine-induced hypothermia in mice by GABA agonists and CCK-8

1. Amphetamine-induced hypothermia in mice is facilitated by dopaminergic stimulation and 5-hydroxytryptaminergic inhibition. The present study was designed to investigate: (a) the involvement of other neuronal systems, such as the gamma-aminobutyric acid (GABA), the opioid and the cholecystokinin (CCK-8) systems; (b) the possible contribution of hydroxylated metabolites of amphetamine to the hypothermia; (c) the capacity of dopamine itself to induce hypothermia and its mechanisms, in order to clarify the resistance of amphetamine-induced hypothermia to certain neuroleptics. 2. Pretreatment with the GABA antagonists, bicuculline and picrotoxin, did not inhibit amphetamine-induced hypothermia. The GABAB agonist, baclofen (2.5 mg kg-1, i.p.) potentiated this hypothermia, whereas the GABAA agonist, muscimol, did not. gamma-Butyrolactone (GBL) (40 mg kg-1, i.p.) and the neuropeptide CCK-8 (0.04 mg kg-1, i.p.) also induced potentiation. The opioid antagonist, naloxone, was without effect. 3. Dopamine itself (3, 9, 16 and 27 micrograms, i.c.v.) induced less hypothermia than the same doses of amphetamine. Sulpiride did not block dopamine-induced hypothermia, but pimozide (4 mg kg-1, i.p.), cis(z)flupentixol (0.25 mg kg-1, i.p.) and haloperidol (5 micrograms, i.c.v.) did. The direct dopamine receptor agonist, apomorphine, did not alter the hypothermia. Neither the 5-hydroxytryptamine (5-HT) receptor blocker, cyproheptadine, nor the inhibitor of 5-HT synthesis, p-chlorophenylalanine (PCPA), modified dopamine-induced hypothermia. Fluoxetine, an inhibitor of 5-HT reuptake, had no effect, whereas quipazine (6 mg kg-1, i.p.), a 5-HT agonist, totally prevented the hypothermia. Hypothermia was unaffected by pretreatment with CCK-8. 4. These data indicate that the hypothermia induced by amphetamine involves not only dopaminergic and 5-hydroxytryptaminergic systems which are functionally antagonistic, but is also facilitated by direct or indirect GABA and CCK-8 receptor stimulation. This facilitation could result, in part, from modulation of dopaminergic neurotransmission. This may explain the apparent resistance of amphetamineinduced hypothermia to some neuroleptics, while dopamine-induced hypothermia is not resistant. The possible action of hydroxylated metabolites of amphetamine may also help to explain these differences.

Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia

To substantiate a previously reported disturbance of gamma-aminobutyric acid (GABA) in chronic schizophrenia, plasma growth hormone (GH) response to a direct GABA agonist (baclofen, 10 mg) was assessed in 12 unmedicated chronic schizophrenic males and 10 sex- and age-matched healthy controls. Baclofen and placebo were administered orally, in a double-blind design, and blood samples were collected before and 30, 60, 90, 120, 180, and 240 min after drug or placebo administration. Baclofen induced a clear-cut rise in plasma GH levels over baseline values, but the GH increase observed in the patients was significantly smaller than that in controls. These results support the idea that GABA mechanisms may be impaired in chronic schizophrenia.

Alterations in amphetamine stereotypy following acute lesions of substantia nigra

Stereotypy induced by high doses of amphetamine has been related to the ability of this drug to increase the release of dopamine in the caudate nucleus and to block its reuptake. Since amphetamine-stimulated dopamine release in the caudate is blocked by acute lesions of the nigrostriatal pathway, the mechanism by which amphetamine acts to produce stereotypy may be dependent upon intact nigrostriatal impulse flow. The present study examined the involvement of nigrostriatal impulse flow in amphetamine stereotypy by determining the effect of acute, bilateral lesions of substantia nigra pars compacta on measures of stimulant-induced stereotypy and motility. Acute nigral lesions did not significantly alter the stereotypy or motility induced by 3.0 or 6.0 mg/kg amphetamine. These results suggest that the observed behavioral effects of amphetamine do not require an intact nigrostriatal pathway, and thus may involve changes in spontaneous release or reuptake of dopamine rather than in changes in impulse-coupled dopamine release.

Clonidine reverses baclofen-induced increases in noradrenaline turnover in rat brain

The effect of baclofen and clonidine, both individually and in combination, on noradrenaline turnover was examined in several brain regions as well as in the spinal cord using the alpha-methyl-p-tyrosine depletion method. Baclofen (30-50 mg/kg) consistently increased the turnover of noradrenaline in the cortex, hippocampus and spinal cord and this effect was stereoselective for the L-isomer. Clonidine (0.1 mg/kg) decreased noradrenaline turnover in these regions and reversed the effect of baclofen. In the striatum, baclofen (50 mg/kg) decreased the turnover of dopamine in a stereoselective manner. Clonidine (0.1 mg/kg) did not alter dopamine turnover but potentiated the effect of baclofen. These results support behavioural data which suggests that baclofen interacts with central noradrenergic pathways. The nature of such interactions appears to be complex.

Dopamine receptor-mediated regulation of incertohypothalamic dopaminergic neurons in the male rat

The incertohypothalamic dopaminergic (DA) neuronal system has been divided into a rostral component of neurons originating in the rostral periventricular nucleus and projecting to the preopticosuprachiasmatic and medial preoptic nuclei and a caudal component originating in the medial zona incerta and projecting to the dorsomedial and anterior hypothalamic nuclei. The purpose of the present study was to determine if the activity of these intrahypothalmic DA neurons is regulated by DA receptor-mediated mechanisms, as are those in the major ascending nigrostriatal and mesolimbic neurons, or if they resemble another group of intrahypothalamic DA neurons, those that comprise the tuberoinfundibular system, which are not responsive to the acute actions of DA agonists or antagonists. The rate of DA turnover (decline after alpha-methyltyrosine) in micropunched regions of the striatum (ST), nucleus accumbens (NA) and hypothalamic regions which contain cell bodies or terminals of incertohypothalamic DA neurons was increased after administration of a DA antagonist (haloperidol) and decreased after administration of a DA agonist (bromocriptine). gamma-Butyrolactone increased DA concentrations in the ST, NA and hypothalamic brain regions containing incertohypothalamic DA neurons, and this effect was blocked by the DA agonist apomorphine. In contrast, none of these treatments affected the concentration or rate of turnover of DA in the median eminence (terminal region of tuberoinfundibular neurons). Injections of either gamma-hydroxybutyric acid or baclofen into the substantia nigra/ventral tegmental region of the midbrain increased DA concentrations in the NA and/or ST but failed to alter DA concentrations in any hypothalamic region. These results suggest that the incertohypothalamic DA system is composed of neurons whose activity can be rapidly modulated by DA receptor-mediated mechanisms and thus resemble the DA neurons in the major ascending nigrostriatal and mesolimbic systems rather than the hypothalamic neurons which comprise the tuberoinfundibular DA system.

Sensorimotor impairment and elevated levels of dopamine metabolites in the neostriatum occur rapidly after intranigral injection of 6-hydroxydopamine or gamma-hydroxybutyrate in awake rats

The unilateral injection of 6-hydroxydopamine (8 micrograms) into the ventral tegmental area of awake rats produced a rapidly developing and irreversible sensory neglect to contralateral tactile stimuli. This neglect developed in a caudal to rostral direction on the affected body surface and coincided with significant elevation in the concentrations of dopamine and two of its metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the ipsilateral neostriatum. The unilateral injection of procaine or gamma-hydroxybutyric acid (GHB) into the substantia nigra of awake animals also produced a contralateral neglect that developed in a caudal to rostral direction, but the behavioral effect of these drugs diminished within 1 hr. Concentrations of dopamine, dihydroxyphenylacetic acid and homovanillic acid in the neostriatum were markedly elevated during continuous infusions of procaine or gamma-hydroxybutyric acid. The extent of sensory neglect and changes in dopamine metabolism in the neostriatum varied according to the amount of gamma-hydroxybutyric acid injected into the nigra and according to the proximity of injections of gamma-hydroxybutyric acid to the pars compacta. The rapid onset of sensory neglect following microinjections of 6-hydroxydopamine, procaine or gamma-hydroxybutyric acid is consistent with the ability of each of these drugs to block the conduction of impulses in mesostriatal neurons and suggests that concomitant increases in levels of dopamine, dihydroxyphenylacetic acid and homovanillic acid in the neostriatum resulted from decreases in the release of dopamine coupled with increased synthesis of dopamine. These findings also indicate that the catabolism of dopamine to dihydroxyphenylacetic acid or homovanillic acid may originate intraneuronally, without prior release of dopamine and its recapture by mesostriatal terminals, if the flow of impulses in this pathway has been blocked.

Role of nigral dopamine in amphetamine-induced locomotor activity

Dopamine (100 micrograms) injected into the substantia nigra pars reticulata of rats pretreated with the monoamine oxidase inhibitor, pargyline, resulted in a stimulation of locomotor activity. Bilateral injection of the dopamine antagonist haloperidol (5 micrograms) into the substantia nigra pars reticulata resulted in a reduction of the locomotor activity evoked by a low dose of amphetamine (1.25 mg/kg s.c.). These results suggest that the release of dopamine from nigral dendrites is involved in amphetamine-induced locomotor activity.

Nigral dopaminergic mechanisms in drug-induced circling

Unilateral injections of dopamine into the substantia nigra pars reticulata of pargyline-pretreated rats caused a prolonged, contralateral circling, similar in magnitude to that elicited by the injection of the same amount of dopamine intrastriatally. Contralateral circling was also elicited by the unilateral intranigral injection of amphetamine (after pargyline pretreatment), or by the dopamine agonists ergometrine and SKF 38393. In contrast, bilateral intranigral injection of the dopamine antagonist haloperidol greatly reduced the amphetamine-induced circling of rats with unilateral 6-hydroxydopamine-induced nigrostriatal lesions. These results support the hypothesis that dopaminergic mechanisms in the substantia nigra are involved in motor behavior.

Naloxone does not alter the effect of gamma aminobutyric acid derivative, baclofen, on GH release in man

To evaluate the interaction between opioid peptides and GABAergic system in regulating GH secretion we administered 5 mg of baclofen, a GABA derivative, to eight normal male subjects. The results were compared to those obtained in the same subjects treated with naloxone (10 mg/2 h) plus baclofen. GH levels increased significantly above basal value either after baclofen and naloxone plus baclofen without any significant difference between GH responses during the two tests. It is suggested that the two substances do not act at the level of the same receptor site. The evaluation of a possible interaction between opioid peptides and GABAergic system on GH release requires further investigation.

Monoamines as mediators of the antinociceptive effect of baclofen

The antinociceptive activity of baclofen was evaluated in rats using the tail flick and hot plate tests. When baclofen was administered intraperitoneally, pretreatment with depletors of monoamines and catecholamines (reserpine, alpha-MPT) produced a marked increase in antinociceptive activity in both tests. Blockade of noradrenergic and dopaminergic receptors with phentolamine, chlorpromazine and haloperidol produced similar increases. These agents were without intrinsic effect in these tests except for alpha-MPT which increased the tail flick latency slightly. Alterations in serotonergic function did not consistently alter the action of baclofen. When baclofen was administered intrathecally, pretreatment with reserpine and alpha-MPT produced minimal alterations in antinociceptive activity. It is likely that interactions between baclofen and monoamines occur at supraspinal sites.

Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice

In male Swiss mice, muscimol produced myoclonic jerks. A 3 mg/kg (i.p.) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min. Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect. However, in a similar experiment l-dopa (80-160 mg/kg) was without effect. In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol. Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks. While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property. Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition. Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.

Effects of electrolytic and 6-hydroxydopamine lesions of the lateral hypothalamus on rotation evoked by electrical stimulation of the substantia nigra in rats

Contralateral rotation evoked by electrical stimulation of the left substantia nigra was studied in rats before and after electrolytic or 6-hydroxydopamine (6-OHDA) lesions of the lateral hypothalamus. Electrolytic lesions (2 mA DC, 15 sec) which produced mean ipsilateral striatal dopamine depletion of 58% significantly reduced the rotation at 2 h to 14 days postlesion. 6-OHDA (8 microgram in 4 microliter) which produced mean ipsilateral striatal dopamine depletion of 93% significantly increased the rotation at 3 to 14 days postlesion. Haloperidol 0.1 and 0.5 mg/kg i.p. partially reduced rotation in both control and lesioned rats in a dose-related manner. Control and lesioned rats showed no significant differences in haloperidol sensitivity. If stimulus induced rotation were mediated by activation of dopaminergic neurons, one would have expected lesion effects in the present experiments to parallel those on rotation caused by pharmacologically evoked release of dopamine. The lesions effects we obtained on stimulus induced rotation, however, parallel those on rotation evoked by the predominantly directly acting dopamine agonist, apomorphine, rather than those on rotation evoked by the indirect (presynaptic) action of amphetamine. We suggest that contralateral rotation evoked by electrical stimulation of the substantia nigra may reflect direct activation of neurons postsynaptic to the dopaminergic nigrostriatal neurons.

GABA antagonists enhance dopamine turnover in the rat retina in vivo

Previous results provided evidence for an inhibitory GABAergic influence on the dopamine neurons of the rat retina, without proving that endogenous GABA physiologically regulates the activity of these cells. We injected picrotoxinin intraocularly to dark-adapted rats and measured retinal dopamine turnover. Dopamine was analyzed radioenzymatically, and the decline in dopamine after alpha-methyl-p-tyrosine was used as an index of dopamine turnover. Picrotoxinin significantly stimulated dopamine turnover (P less than 0.05). In similar experiments with light-exposed rats picrotoxinin slightly enhanced dopamine turnover beyond that produced by light alone. Intraocular bicuculline methiodide produced similar results in dark-adapted and also in light-exposed rats. These data suggest that endogenous GABA tonically inhibits the activity of the retinal dopamine neurons in the dark and that there may be some remaining GABA tone on these cells in the light-exposed rat. Atropine pretreatment did not affect the picrotoxinin-induced activation of retinal dopamine turnover which negates the involvement of a cholinergic interneuron.

Dyskinesia: animal experimental correlates

The results of behavioral studies in animals, which demonstrate increased effects of DA agonists after stopping chronic administration of neuroleptics, are consistent with an increased sensitivity of postsynaptic receptor and effector mechanisms in response to chronic disruption of DA transmission (disuse supersensitivity of DA receptors, see review by Moore & Thornburg (1975)). Although this mechanism may be responsible for the reversible withdrawal dyskinesias, it is probably not involved in persistent tardive dyskinesia. The persistence of the latter dyskinesias suggests an irreversible structural or chemical change, but with the exception of a report by Christensen et al. (1970) there is little evidence of neuroleptic-induced degenerative changes in the brains of man or animals. Although the etiology of tardive dyskinesias remains a mystery, pharmacological evidence suggests a functional overactivity of extrapyramidal mechanisms mediated by DA. To date, however, experiments with animal models have not provided a logical explanation for this overactivity.

Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice

In the electroshock test--taking hind-limb tonic extension as the end point--apomorphine (10 mg/kg) exerted no effect on the anticonvulsant action of phenobarbital (PB; 20 mg/kg) or diphenylhydantoin (DPH; 8 mg/kg); amantadine (25 and 100 mg/kg) decreased that of DPH, while L-DOPA (500 mg/kg) and d,l-amphetamine (10 mg/kg) potentiated the action of both anticonvulsants. Fluphenazine (4 mg/kg) had no influence on the effects of the two anticonvulsants, but haloperidol lessened that of DPH. All GABA-ergic stimulants used, i.e., gamma-hydroxybutyric acid (GHBA/250 mg/kg), baclofen (2.5 and 10 mg/kg) and aminooxoacetic acid (AOAA; 15 and 20 mg/kg) potentiated the action of PB; the action of DHP was unaffected by these drugs except for AOAA (20 mg/kg). The combined treatment with dopaminergic and GABA-ergic stimulants, being ineffective in terms of anticonvulsant activity, resulted in a marked potentiation of the action of the anticonvulsants tested in this study. The most distinct potentiation was noted in the case of PB, baclofen (1 mg/kg), and amantadine (25 mg/kg).

Removal of the telencephalon spares turning induced by injection of GABA agonists and antagonists into the substantia nigra

Unilateral injections into the substantia nigra of GABA agonists or the GABA-related agents muscimol (5-50 ng), baclofen (10-50 ng) or B-aminobutyric acid (25-50 ug) induced intensive turning in the direction contralateral to the injected hemisphere. Intranigral injection of the GABA antagonist picrotoxin (100-500 ng) led to ipsiversive turning. Surgical removal of the whole telencephalon (including the neocortex, hippocampus, striatum, septal nuclei and amygdalae) influenced neither direction nor magnitude of the turning responses induced by these various drugs. A GABAergic system in the substantia nigra can, therefore, cause turning independent of telencephalic structures.

Differential behavioral and biochemical effects of four dopaminergic agonists

Some behavioral and biochemical effects of four dopaminergic agonists (apomorphine, piribedil, lergotrile, and bromocriptine) were determined in the mouse. As expected, all four drugs dose-dependently reversed the alpha-methyltyrosine-induced decline of forebrain dopamine. All four compounds reduced locomotor activity at low doses, but only apomorphine and bromocriptine increased motor activity at higher doses. All four drugs caused some reversal of the baclofen-induced elevation in forebrain dopamine concentrations, but only apomorphine and bromocriptine completely reversed the effects of baclofen. After chronic treatment with haloperidol, the behavioral effects of lergotrile and bromocriptine were altered. Doses of those drugs reducing motor activity in normal animals were ineffective after chronic haloperidol. The latent stimulation induced by bromocriptine was enhanced, while a stimulatory effect of lergotrile emerged in these animals. These effects were noted in conjunction with an enhanced sensitivity to the drug-induced decrease in dopamine turnover. These results demonstrate that dopamine agonists may be differentiated on the basis of certain behavioral and biochemical tests and suggest an interaction of these drugs with two different populations of dopamine receptors.

Ketamine-induced rotation: interaction with GABA-transaminase inhibitors and picrotoxin

Ketamine in a dose of 100 mg/kg (IP) produced stereotypic behavior and vigorous rotation in adult male Sprague-Dawley rats. The first rotation phase, accompanied by head swinging, was short and terminated by the anesthetic phase which lasted 20-30 min. The second rotation phase began 1-3 min after the end of the anesthetic phase. A single dose of GABA-T inhibitors, gamma-vinyl GABA (1200 mg/kg, IP) or gamma-acetylenic GABA (100 mg/kg, IP) administered 4 hours prior to ketamine, shortened the first rotation phase, increased the anesthetic phase, changed the pattern of postanesthetic rotation and reduced total and net rotation scores. Picrotoxin (3 mg/kg) given 10 min prior to ketamine tended to act in the opposite direction although none of its effects reached statistical significance.

Effects of intranigral administration of dopamine agonists and antagonists and baclofen on concentrations of dopac and dopamine in the striatum and substantia nigra of the rat

Systemic administration of haloperidol to rats failed to alter the concentration of dopamine but increased the concentration of 3,4-dihydroxy-phenylacetic acid (DOPAC), the major metabolite of dopamine, in both the striatum and substantia nigra. These haloperidol-induced changes in DOPAC were prevented by an intranigral microinjection of baclofen, a drug which reduces nigrostriatal dopaminergic neuronal activity. It has been proposed that nigrostriatal neurons are regulated, in part, by the activation of autoreceptors in substantia nigra. However, intranigral microinjections of high concentrations of several dopaminergic antagonists failed to mimic the biochemical effects resulting from systemic administration of these drugs; instead, they slightly increased the concentrations of both dopamine and DOPAC in the striatum and decreased dopamine in substantia nigra. Intranigral microinjections of the dopamine agonist, apomorphine, failed to alter the concentration of DOPAC in the striatum, but reduced both dopamine and DOPAC in the nigra. If DOPAC concentrations reflect nigrostriatal dopaminergic neuronal activity, the present results suggest that dopaminergic agonists and antagonists acting in substantia nigra do not exert a major influence on the activity of these neurons.

Baclofen and muscimol: behavioural and neurochemical sequelae of unilateral intranigral administration and effects on 3H-GABA receptor binding

Log dose-response curves for induction of contralateral rotational behaviour in the rat by unilateral intranigral injections of the GABA agonist muscimol and the GABA analogue baclofen have been compared. Baclofen, 5--1000 ng, produced a maximal rotational response that was only 40% of that produced by 0.25--100 ng muscimol, and log dose-response curves failed to show parallelism. The behavioural effects of both drugs were only weakly antagonised by haloperidol and were not antagonised by 6-hydroxydopamine lesions of ipsilateral dopamine (DA) neurons, indicating that these responses were independent of DAergic mechanisms. The effects of baclofen were weakly antagonised by picrotoxin. Intranigral muscimol and baclofen substantially elevated striatal DA concentrations. While muscimol also substantially elevated striatal dihydroxyphenylacetic acid (DOPAC) but not homovanillic acid (HVA), bactofen did not significantly effect either DOPAC or HVA. Baclofein, GABA and muscimol displaced specific 3H-GABA binding in vitro with IC50's of 40 micron, 400 nM and 40 nM respectively. These results indicate that muscimol and baclofen do not act via a unitary GABAergic mechanism, but suggest that baclofen may be a partial GABA agonist, at least at nigral GABA receptors.

Effects of baclofen on striatal 5-HT mediated by the nigrostriatal dopamine system

In rats, baclofen injected unilaterally into the substantia nigra increased dopamine (DA) and serotonin (5-HT) levels in the ipsilateral striata. Homovanillic acid levels first decreased and then increased to a maximum after 4 h. The content of 3,4-dihydroxyphenylacetic acid also increased after a latency of about 1 h. The effects of baclofen on striatal DA metabolism are consistent with the assumption that impulse flow in these DA neurones was diminshed by the drug. DA metabolites were also found in greater quantities in the contralateral striata, probably owing to compensatory activation of these DA neurones. Baclofen injected intranigrally did not increase the striatal 5-HT content in rats with a 6-hydroxydopamine-induced lesion of the nigrostriatal DA pathway. Our results suggest the presence of DA receptors on striatal 5-HT terminals or on interneurones synapsing axo-axonally with them.

Sites of action of amphetamine intrinsic to catecholaminergic nuclei: catecholaminergic presynaptic dendrites and axons

1. It is now well established that the behavioral actions of amphetamine, especially locomotor and stereotyped behaviors, are dependent in part upon the release of catecholamines in the central nervous system. 2. A variety of empirical evidence has established that the release of catecholamines by amphetamine leads to changes in neuronal activity in regions postsynaptic to catecholaminergic nerve terminals. In addition, release of catecholamines is accompanied by a marked inhibition of neuronal firing in catecholaminergic neurons. 3. At least two conceptions have been advanced to account for this marked decrease in catecholaminergic neuronal activity. (a) In one of these, release of catecholamines from presynaptic terminals is thought to lead to a compensatory decrease in neuronal firing rate by means of a postsynaptic neuronal feedback loop from regions innervated by catecholaminergic neurons. (b) In the other, decreased neuronal activity is hypothesized to result from local release of catecholamines onto or near catecholaminergic neuronal dendrites and somata, a phenomenon that has been characterized as self-inhibition. 4. For dopaminergic neurons, recent biochemical, neuropharmacological and neuroanatomical evidence suggests that the latter process could be subserved by dopamine released from dopaminergic neuronal dendrites, i.e., "presynaptic" dendrites.